Vetter's Chicago Facility Fully Operational - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Vetter's Chicago Facility Fully Operational

Sponsored by:Vetter

Peter Soelkner
Managing Director
Vetter Pharma International GmbH

Add this Podcast feed to your media player

In 2010, Vetter brought you up to date on the company’s plans to expand its Vetter Development Service operations by opening its first manufacturing site outside of Germany. Just recently, Vetter announced that the site, located in Chicago at the Illinois Science + Technology Park in Skokie, is fully operational. Among the sites attributes, which include state-of-the-art systems and infrastructure, coupled with professional expertise, the facility is the first to use a new fully automated vial filler designed specifically for early-clinical stage, high-value biopharmaceuticals.



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here